ArticleNature reviews. Rheumatology2025
2023 International Rome consensus for the nomenclature of Sjögren disease.
Article in Nature reviews. Rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond anti-SSA and anti-SSB. The clinical significance of new antibodies in the diagnosis of Sjögren disease.Rheumatology international · 2026Pooled it
- Salivary gland SPECT/CT of parotid glands in patients with lymphoepithelial sialadenitis: preliminary study on clinical and pathological features.Oral radiology · 2026Article
- [How often do patients with Sjögren's syndrome fulfil the activity criteria for immunomodulatory treatment?]Zeitschrift fur Rheumatologie · 2026Article
- Can dentists recognise the hidden burden of Sjögren disease beyond xerostomia?Evidence-based dentistry · 2026Article
- Ophthalmic Treatments and Evolving Management of Sjögren's Disease: An Overview.Journal of clinical medicine · 2026Review
- [Proposal of the rheumatology societies in the D-A-CH region for a uniform German nomenclature for Sjögren's disease].Zeitschrift fur Rheumatologie · 2026Article
- T Cell-Derived IFN-γ Activates Ferroptosis in Lacrimal Luminal Ductal Cells via JAK-STAT Signaling in Sjögren's Disease-Related Dry Eye.Investigative ophthalmology & visual science · 2026Article
- [Diagnostics of Sjögren's disease].Zeitschrift fur Rheumatologie · 2026Review
- [Pathophysiological aspects of primary Sjögren's disease : From epithelial activation to systemic autoimmunity].Zeitschrift fur Rheumatologie · 2026Review
- [Epidemiology and manifestations of Sjögren's disease].Zeitschrift fur Rheumatologie · 2026Article
- [Practical management of Sjögren's disease in the era of new treatment options : Current value of available outcome parameters].Zeitschrift fur Rheumatologie · 2026Article
- Medication adherence is associated with the necessity-concern differential in newly diagnosed primary Sjögren disease: a prospective observational cohort study.Rheumatology international · 2026Observational
- Photobiomodulation for salivary gland dysfunction: aligning clinical expectations with etiology-dependent treatment responsiveness.Lasers in medical science · 2026Review
- Cytokine Networks and Clinical Heterogeneity in Sjögren's Disease: From Glandular Inflammation to Therapeutic Stratification.International journal of molecular sciences · 2026Review
- Inflammasomes in Sjögren's Disease: Exploring the Therapeutic Value.International journal of molecular sciences · 2026Review
- Age-specific reference values for unstimulated whole saliva flow rate in primary Sjögren's syndrome: a cross-sectional study.BMC oral health · 2026Article
- From Sjögren syndrome to Sjögren disease: rethinking classification and diagnostic complexity.The Korean journal of internal medicine · 2026Review
- Leukopenia and systemic features in Sjögren's disease: a retrospective hospitalized cohort study.Clinical rheumatology · 2026Article
- Review
- Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nomenclature for the disease widely known as Sjögren syndrome has proven unsatisfactory. Patients have perceived 'syndrome' as indicative of a vague collection of symptoms, prompting the Sjögren's Foundation to abandon the term. Furthermore, the traditional distinction between 'primary' and 'secondary' forms fails to account for the complex interplay between overlapping autoimmune diseases. Following a bibliometric analysis, systematic literature review and a Delphi consensus process with equal involvement of professional and patient representatives, five recommendations are now issued. First, the term 'Sjögren disease' should replace 'Sjögren syndrome'. Second, the acronym 'SjD' should be used as an abbreviation for 'Sjögren disease'. Third, the descriptor 'associated' should be used in lieu of 'secondary' for Sjögren disease occurring in association with a second systemic autoimmune disease for which classification criteria are fulfilled. Fourth, Sjögren disease is the preferred terminology in common parlance and in clinical diagnosis, without differentiation as to primary and associated forms. Fifth, the differentiation between primary and associated Sjögren is recommended for scientific studies to define a homogeneous population. In conclusion, the consensus endorses 'Sjögren disease' as the official nomenclature to acknowledge the distinct pathogenesis of this disorder and to improve clarity in both clinical practice and research.
Indexed as
Identifiers
40494962What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.